as reported June 1, 2002
FDA Approves Biocon’s Avastin Biosimilar
Jobevne is the fifth Avastin biosimilar, which are recombinant humanized monoclonal antibodies used to treat several different types of cancer.
Read More
Payers Consider Policy Options for Access to GLP-1 Obesity Medications
A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.
FDA Announces Goal Date for Resubmitted Bevacizumab to Treat Wet AMD
The FDA has set a goal date of Aug. 27, 2025. If approved, the therapy would be branded as Lytenava and be the first ophthalmic formulation of bevacizumab.
Bkemv and Epysqli, Two Biosimilars of Soliris, are Now Available
Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the same rare immune diseases as Soliris.
FDA Approves Uplizna for Chronic Inflammatory Condition IgG4-RD
Uplizna is the first approved treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition that can affect multiple organs. It has a price of $140,248.50 per dose.
FDA Grants Accelerated Approval to Vanrafia for IgAN, a Rare Kidney Disease
Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost of $162,500 annually.
